- Home
- PBFS vs IMMP Comparison
PBFS vs IMMP Comparison
Compare PBFS & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBFS
- IMMP
- Stock Information
- Founded
- PBFS 1889
- IMMP 1987
- Country
- PBFS United States
- IMMP Australia
- Employees
- PBFS N/A
- IMMP N/A
- Industry
- PBFS Banks
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- PBFS Finance
- IMMP Health Care
- Exchange
- PBFS Nasdaq
- IMMP Nasdaq
- Market Cap
- PBFS 309.6M
- IMMP 304.0M
- IPO Year
- PBFS N/A
- IMMP N/A
- Fundamental
- Price
- PBFS $11.98
- IMMP $1.81
- Analyst Decision
- PBFS
- IMMP Buy
- Analyst Count
- PBFS 0
- IMMP 2
- Target Price
- PBFS N/A
- IMMP $8.50
- AVG Volume (30 Days)
- PBFS 25.2K
- IMMP 82.5K
- Earning Date
- PBFS 05-12-2025
- IMMP 03-25-2025
- Dividend Yield
- PBFS N/A
- IMMP N/A
- EPS Growth
- PBFS 6.93
- IMMP N/A
- EPS
- PBFS 0.76
- IMMP N/A
- Revenue
- PBFS $88,118,000.00
- IMMP $3,019,249.00
- Revenue This Year
- PBFS N/A
- IMMP N/A
- Revenue Next Year
- PBFS N/A
- IMMP $20.28
- P/E Ratio
- PBFS $15.79
- IMMP N/A
- Revenue Growth
- PBFS 10.09
- IMMP 24.11
- 52 Week Low
- PBFS $8.76
- IMMP $1.65
- 52 Week High
- PBFS $12.20
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- PBFS 57.37
- IMMP 41.69
- Support Level
- PBFS $11.76
- IMMP $1.65
- Resistance Level
- PBFS $12.05
- IMMP $1.88
- Average True Range (ATR)
- PBFS 0.24
- IMMP 0.10
- MACD
- PBFS -0.01
- IMMP -0.01
- Stochastic Oscillator
- PBFS 62.71
- IMMP 41.94
About PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.